Chromane, isochromane and dihydroisobenzofuran derivatives as mGluR2-negative allosteric modulators, compositions, and their use
The present invention provides certain substituted chromane, isochromane, and dihydroisobenzofuran compounds of formula (I): or a pharmaceutically acceptable salt thereof, wherein ring A is a moiety selected from: and ring B, n, R 1 , R 2 , R 2A , R 3 , and R 3A are as defined herein. The compounds of the invention are useful as mGluR2 inhibitors, or mGluR2 negative allosteric modulators (NAMs), and may be useful in methods of treating a patient for diseases or disorders in which the mGluR2-NAM receptor is involved, such as Alzheimer's disease, cognitive impairment, mild cognitive impairment, schizophrenia and other mood disorders, pain disorders and sleep disorders, by administering to the patient a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof. The invention is also directed to pharmaceutical compositions comprising a compound of the invention, or a pharmaceutically acceptable salt thereof, (optionally in combination with one or more additional active ingredients), and a pharmaceutically acceptable carrier, and the use of the compounds and pharmaceutical compositions of the invention in the treatment of such diseases.
1. A compound of Formula (I):
or a stereoisomer thereof, or a pharmaceutically acceptable salt of said compound or said stereoisomer, wherein:
ring A is a moiety selected from:
R 2 is selected from H, cyclopropyl, —(C 1 -C 4 )alkyl, —(C 1 -C 4 )alkyl-OH, —(C 1 -C 4 )alkyl-OCH 3 , —(C 1 -C 4 )haloalkyl, —(C 1 -C 4 )alkyl-O—(C 1 -C 4 )haloalkyl, —CH(CH 3 ) 2 , —CH 2 —O—(C 1 -C 4 )haloalkyl, —CH(CH 3 )—O—(C 1 -C 4 )haloalkyl, —CH 2 —NH—(C 1 -C 4 )haloalkyl, and —CH 2 —N(CH 3 )—(C 1 -C 4 )haloalkyl,
R 2A is selected from H and methyl;
R 3 is selected from H and methyl;
R 3A is selected from H and methyl;
ring B is a moiety selected from the group consisting of phenyl, heteroaryl, —(C 5 -C 6 ) cycloalkyl, and —(C 5 -C 6 ) cycloalkenyl;
n is 0, 1, 2, or 3, provided that the value of n does not exceed the maximum number of substitutable hydrogen atoms on ring B; and
each R 1 (when present) is independently selected from the group consisting of halogen, —CN, —OH, —(C 1 -C 6 ) alkyl, —O—(C 1 -C 6 ) alkyl, —(C 1 -C 6 ) haloalkyl, —O—(C 1 -C 6 ) haloalkyl, cyclopropyl, cyclobutyl, —NH 2 , —NH(C 1 -C 6 )alkyl, —N(C 1 -C 6 alkyl) 2 , —C(O)O(C 1 -C 6 ) alkyl, and phenyl.
2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof,
having the Formula (IA):
wherein B, n, R 1 , R 2 , R 2A , R 3 and R 3A are as defined in claim 1 .
3. The compound of claim 2 , or a pharmaceutically acceptable salt thereof,
wherein R 2 is selected from H, cyclopropyl, —CH 3 , —CH(CH 3 ) 2 , —CH 2 —OH, —CH 2 —OCH 3 , —CH 2 F, —CHF 2 , —CF 3 , —CH 2 CH 2 F, —CH 2 CHF 2 , —CH 2 CF 3 , —CH 2 —O—CH 2 F, —CH 2 —O—CHF 2 , —CH(CH 3 )—O—CH 2 F, —CH(CH 3 )—O—CHF 2 , —CH 2 —NH—CH 2 CF 3 , and —CH 2 —N(CH 3 )—CH 2 CF 3 ;
R 2A is selected from H and methyl;
R 3 is selected from H and methyl; and
R 3A is selected from H and methyl.
4. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein
R 2 and R 2A are both methyl; and
R 3 and R 3A are both H.
5. The compound of claim 1 , or a pharmaceutically acceptable salt thereof,
having the Formula (IB):
wherein B, n, and R 1 are as defined in claim 1 .
6. The compound of claim 1 , or a pharmaceutically acceptable salt thereof,
having the Formula (IC):
wherein B, n, and R 1 are as defined in claim 1 .
7. The compound of claim 1 , or a pharmaceutically acceptable salt thereof,
having the Formula (ID):
wherein B, n, and R 1 are as defined in claim 1 .
8. The compound of claim 2 , or a pharmaceutically acceptable salt thereof,
ring B is a moiety selected from the group consisting of phenyl, cyclopentyl, cyclohexyl, pyridinyl, pyrimidinyl, pyrazolyl, thienyl, thiazolyl, thiadiazolyl, isoxazolyl, oxadiazolyl and oxazolyl;
n is 0, 1, 2, or 3, provided that the value of n does not exceed the maximum number of substitutable hydrogen atoms on ring B; and
each R 1 (when present) is independently selected from the group consisting of halogen, —CN, —OH, —(C 1 -C 6 ) alkyl, —O—(C 1 -C 6 ) alkyl, —(C 1 -C 6 ) haloalkyl, —O—(C 1 -C 6 ) haloalkyl, cyclopropyl, cyclobutyl, —NH 2 , —NH(C 1 -C 6 )alkyl, —N(C 1 -C 6 alkyl) 2 , —C(O)O(C 1 -C 6 ) alkyl, and phenyl.
9. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein:
ring B is a moiety selected from the group consisting of: phenyl, pyrazolyl, pyridinyl, thienyl, isoxazolyl, oxadiazolyl and oxazolyl;
n is 0, 1, or 2; and
each R 1 (when present) is independently selected from the group consisting of fluoro, chloro, —CH 3 , and —CHCF 2 .
10. The compound of claim 1 , having the Formula (IA-1):
or a stereoisomer thereof or a pharmaceutically acceptable salt of said compound or said stereoisomer, wherein:
R 2 is selected from H, cyclopropyl, —CH 3 , —CH(CH 3 ) 2 , —CH 2 —OH, —CH 2 —OCH 3 , —CH 2 F, —CHF 2 , —CF 3 , —CH 2 CH 2 F, —CH 2 CHF 2 , —CH 2 CF 3 , —CH 2 —O—CH 2 F, —CH 2 —O—CHF 2 , —CH(CH 3 )—O—CH 2 F, —CH(CH 3 )—O—CHF 2 , —CH 2 —NH—CH 2 CF 3 , and —CH 2 —N(CH 3 )—CH 2 CF 3 ;
R 2A is selected from H and CH 3 ;
R 3 is selected from H and CH 3 ; and
R 3A is selected from H and CH 3 .
11. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, said compound selected from the group consisting of:
12. A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.